HANSOH PHARMA - VOLUNTARY ANNOUNCEMENT - THE CLINICAL TRIAL APPROVAL FOR HS-20152 INJECTION ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

Hansoh Pharmaceutical Group Company Limited

翰森製藥集團有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 3692)

VOLUNTARY ANNOUNCEMENT

THE CLINICAL TRIAL APPROVAL FOR HS-20152 INJECTION

ISSUED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

The board of directors (the "Board") of Hansoh Pharmaceutical Group Company Limited (the "Company" and together with its subsidiaries, the "Group") is pleased to announce that, HS-20152 injection, a Category 1 innovative drug self-developed by the Group, has obtained the Clinical Trial Approval issued by the National Medical Products Administration (NMPA) of China, which is intended to be investigated in clinical trials for paroxysmal nocturnal hemoglobinuria.

By Order of the Board

Hansoh Pharmaceutical Group Company Limited Zhong Huijuan

Chairlady

Hong Kong, March 23, 2026